Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 31
2016 58
2017 67
2018 59
2019 59
2020 11
Text availability
Article attribute
Article type
Publication date

Search Results

259 results
Results by year
Filters applied: . Clear all
Page 1
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ. Landovitz RJ, et al. PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov. PLoS Med. 2018. PMID: 30408115 Free PMC article. Clinical Trial.
BACKGROUND: Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. ...Seven incident sexually transmitted infections were diagnosed in 6 participants. One HIV infection occurred in a participant 48 weeks a …
BACKGROUND: Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. ...Se …
Syndemic factors associated with adherence to antiretroviral therapy among HIV-positive adult heterosexual men.
McMahon JM, Braksmajer A, Zhang C, Leblanc N, Chen M, Aidala A, Simmons J. McMahon JM, et al. AIDS Res Ther. 2019 Nov 9;16(1):32. doi: 10.1186/s12981-019-0248-9. AIDS Res Ther. 2019. PMID: 31706357 Free PMC article.
BACKGROUND: Suboptimal adherence to HIV antiretroviral therapy (ART) and concomitant lack of viral control can have severe consequences for health and onward transmission among persons living with HIV. Little is known about the barriers and facilitators of optimal ART a
BACKGROUND: Suboptimal adherence to HIV antiretroviral therapy (ART) and concomitant lack of viral control can have severe consequenc …
Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.
Milligan MG, Bigger E, Abramson JS, Sohani AR, Zola M, Kayembe MKA, Medhin H, Suneja G, Lockman S, Chabner BA, Dryden-Peterson SL. Milligan MG, et al. J Glob Oncol. 2018 Sep;4:1-11. doi: 10.1200/JGO.17.00084. J Glob Oncol. 2018. PMID: 30241264 Free PMC article.
Currently, there are few data regarding the sociodemographic factors, clinical characteristics, and outcomes of non-Hodgkin lymphoma (NHL)-an AIDS-defining cancer-in the country. ...Treatment patterns and clinical outcomes were analyzed. RESULTS: One hundred four pa …
Currently, there are few data regarding the sociodemographic factors, clinical characteristics, and outcomes of non-Hodgkin lymphoma (NHL)-a …
Trends in ART Prescription and Viral Suppression Among HIV-Positive Young Adults in Care in the United States, 2009-2013.
Beer L, Mattson CL, Bradley H, Shouse RL; Medical Monitoring Project. Beer L, et al. J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e1-e6. doi: 10.1097/QAI.0000000000001427. J Acquir Immune Defic Syndr. 2017. PMID: 28489729 Free PMC article.
We sought to examine trends in treatment and health outcomes from 2009 to 2013 among HIV-positive young adults (aged 18-24 years) in care. ...There was no significant change in adherence, side effects, or regular care utilization. Although viral suppression at last …
We sought to examine trends in treatment and health outcomes from 2009 to 2013 among HIV-positive young adults (aged 18-24 years) in …
Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men.
Patel RR, Crane JS, López J, Chan PA, Liu AY, Tooba R, James AS. Patel RR, et al. PLoS One. 2018 Dec 28;13(12):e0209484. doi: 10.1371/journal.pone.0209484. eCollection 2018. PLoS One. 2018. PMID: 30592756 Free PMC article.
PrEP uptake and adherence remain low and product preferences are unknown, especially among young African American MSM who are most at-risk. ...Most participants preferred a long-acting injectable (LAI) to daily oral pills due to better medication adherence and a dis …
PrEP uptake and adherence remain low and product preferences are unknown, especially among young African American MSM who are most at …
A Reappraisal of Sex-Specific Cancer Survival Trends Among Adolescents and Young Adults in the United States.
Liu L, Moke DJ, Tsai KY, Hwang A, Freyer DR, Hamilton AS, Zhang J, Cockburn M, Deapen D. Liu L, et al. J Natl Cancer Inst. 2019 May 1;111(5):509-518. doi: 10.1093/jnci/djy140. J Natl Cancer Inst. 2019. PMID: 30321398 Free PMC article.
The analysis was conducted with and without Kaposi sarcoma (KS) and lymphomas, and by two time periods: 1973-1977 (before the human immunodeficiency virus/acquired immunodeficiency syndrome [HIV/AIDS] epidemic) and 2005-2009 (after the HIV/AIDS epidemic waned …
The analysis was conducted with and without Kaposi sarcoma (KS) and lymphomas, and by two time periods: 1973-1977 (before the human i …
Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.
Vannappagari V, Thorne C; for APR and EPPICC. Vannappagari V, et al. J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):371-378. doi: 10.1097/QAI.0000000000002035. J Acquir Immune Defic Syndr. 2019. PMID: 30939532 Free PMC article.
METHODS: We reviewed 2 large, independent antiretroviral pregnancy registries to assess birth outcomes associated with maternal dolutegravir treatment during pregnancy. ...CONCLUSIONS: Our findings are reassuring regarding dolutegravir treatment of HIV infection dur …
METHODS: We reviewed 2 large, independent antiretroviral pregnancy registries to assess birth outcomes associated with maternal dolutegravir …
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, Phillips A, Weber R, Fontas E, d' Arminio Monforte A, De Wit S, Dabis F, Hatleberg CI, Sabin C, Mocroft A; D:A:D study group. Ryom L, et al. Lancet HIV. 2018 Jun;5(6):e291-e300. doi: 10.1016/S2352-3018(18)30043-2. Epub 2018 May 3. Lancet HIV. 2018. PMID: 29731407 Clinical Trial.
This association remained after adjustment for time-updated factors on the potential causal pathway; myocardial infarction and stroke separately; plasma bilirubin concentration; and after stratification by use of ritonavir-boosted darunavir as the first ever protease inhib …
This association remained after adjustment for time-updated factors on the potential causal pathway; myocardial infarction and stroke …
Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
Kangethe A, Polson M, Lord TC, Evangelatos T, Oglesby A. Kangethe A, et al. J Manag Care Spec Pharm. 2019 Jan;25(1):88-93. doi: 10.18553/jmcp.2019.25.1.088. J Manag Care Spec Pharm. 2019. PMID: 30589631 Free article.
Qualifying patients were aged ≥ 18 years with a diagnosis of HIV-1 infection or at least 1 pharmacy claim for HIV ART at index and at least 2 pharmacy claims during the follow-up period. Patients were categorized on the basis of adherence as measured by proportion o …
Qualifying patients were aged ≥ 18 years with a diagnosis of HIV-1 infection or at least 1 pharmacy claim for HIV ART at index and at …
259 results
Jump to page
Feedback